Jong-mu Sun
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Response to letter re: "Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study".
Journal: ESMO open
Published: February 18, 2026
Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study.
Journal: ESMO open
Published: September 22, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.
Journal: ESMO open
Published: July 25, 2025
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 08, 2021
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
Journal: ESMO open
Published: December 03, 2021
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 01, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Journal: Lancet (London, England)
Published: March 05, 2021
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Journal: Cancer immunology, immunotherapy : CII
Published: May 29, 2020
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 26, 2020
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 20, 2020
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 20, 2019
Last Updated: 09/26/2026